HoldsUp

Frans Kuypers

Frans Kuypers is a biomedical researcher working in hematology, cellular metabolism, and stem cell biology. His research includes investigating the human placenta as a source of pluripotent and hematopoietic stem cells capable of differentiating into various cell types. His published work focuses extensively on sickle cell disease therapeutics, erythrocyte properties and deformability, and lipid metabolism.

12 claims checked on air: 1 context 1 contradicted 9 supported 1 unverified 1 flagged

What they said on air - supported

1 citing their own research

0:03:39supportedhighDr. Frans Kuypers on Placenta as a Source of Bankable Stem C

Genetic disorders such as sickle cell anemia and thalassemia can only be cured through stem cell transplantation.

"sickle cell and thalassemia, both of them are genetic disorders, and they can only be cured with stem cells." (said at 0:03:39)

Sickle cell disease and beta-thalassemia are monogenic blood disorders. Currently, all established curative treatment modalities rely on hematopoietic stem cells. These include allogeneic hematopoietic stem cell transplantation (allo-HSCT) from a compatible donor and autologous stem cell gene therapy/gene editing (such as exagamglogene autotemcel), in which patient-derived hematopoietic stem cells are genetically modified ex vivo and reinfused. Supportive therapies (such as blood transfusions, iron chelation, and hydroxyurea) manage symptoms and complications but do not provide a cure.

0:03:39supportedhighDr. Frans Kuypers on Placenta as a Source of Bankable Stem C

Children's Hospital Oakland developed the clinical use of sibling umbilical cord blood transplantation to treat leukemia, sickle cell disease, and thalassemia.

"we also developed in this institute the use of cord blood—sibling cord blood—to transplant in individuals with leukemia or sickle cell disease or thalassemia." (said at 0:03:39)

Investigators at Children's Hospital Oakland established the first dedicated Sibling Donor Cord Blood Program in 1998 to collect, bank, and release directed umbilical cord blood units for siblings requiring allogeneic hematopoietic stem cell transplantation. Published cohorts and registry reports from this program demonstrate its development and clinical application for children with malignant disorders (such as leukemia), sickle cell disease, and thalassemia major.

0:04:09supportedhighDr. Frans Kuypers on Placenta as a Source of Bankable Stem C

A standard cord blood unit typically does not contain enough stem cells to successfully treat an adult bone marrow transplant recipient.

"a cord blood unit that is used a lot currently in bone marrow transplant simply doesn't have enough stem cells to cure somebody like you or me. So that's why we started looking at an adult." (said at 0:04:09)

The claim is supported by extensive clinical literature. A standard single umbilical cord blood (UCB) unit typically contains a low cell dose (cell count/CD34+ hematopoietic stem and progenitor cells), which significantly delays or prevents engraftment in adult recipients compared to pediatric recipients. Because cell dose is proportional to recipient body weight (typically requiring at least 2.5 to 3.0 × 10^7 total nucleated cells per kilogram), a single cord blood unit is usually insufficient to safely treat an adult. To overcome this limitation, clinical practice developed strategies such as double-unit cord blood transplantation, ex vivo cell expansion, or searching for adult donors (such as matched unrelated adult donors or haploidentical adult donors).

0:07:33supportedhighDr. Frans Kuypers on Placenta as a Source of Bankable Stem C

One microliter of human blood contains approximately 4 million cells.

"if you take one microliter, which is, you know, one cubic millimeter of blood, it has about 4 million cells in it, okay?" (said at 0:07:33)

Standard hematological reference data confirm that one microliter (equivalent to one cubic millimeter) of human whole blood contains approximately 4 to 6 million cells. The overwhelming majority of these are red blood cells (erythrocytes), which typically range from roughly 3.9 to 5.3 million cells per microliter in adult females and 4.5 to 6.2 million cells per microliter in adult males, alongside 4,000 to 11,000 white blood cells per microliter.

0:09:20supportedlowtheir own paperDr. Frans Kuypers on Placenta as a Source of Bankable Stem C

Frans Kuypers published papers in 2009 and 2012 demonstrating that cells isolated from human term placenta can be cultured to differentiate into multiple cell types such as neurons and heart cells.

"And yes, we have shown in 2009, the paper that you refer to, but we had another paper in 2012 that really shows that in the human term placenta—so this is the placenta that is normally thrown out... you can tease out of those placentas cells that can become any kind of cell in your body." (said at 0:09:20)

Frans Kuypers and colleagues published studies in 2009 and 2012 demonstrating that cells isolated from human term placenta can generate multiple cell lineages. The 2009 study isolated CD34-positive hematopoietic stem and progenitor cells from term placenta that generated erythroid, myeloid, and lymphoid lineages. The 2012 study isolated human chorionic mesenchymal stem cells (hCMSCs) expressing embryonic stem cell markers (such as OCT-4 and NANOG) that demonstrated in vitro differentiation into cell types representing all three germ layers, including neuron-like cells (ectoderm), adipocytes/osteoblasts/endothelial-like cells (mesoderm), and hepatocytes (endoderm).

0:17:12supportedhighDr. Frans Kuypers on Placenta as a Source of Bankable Stem C

Hundreds of children have been successfully cured of blood disorders using cord blood stem cell transplants.

"cord blood is a good example because it has been used and hundreds of kids have been cured with the use of cord blood. So yes, those stem cells that form new blood because it replaces your bone marrow have been used and have been very successful." (said at 0:17:12)

Umbilical cord blood transplantation (UCBT) is an established allogeneic hematopoietic stem cell therapy that has been used successfully to treat and cure thousands of children with malignant and non-malignant hematologic disorders, including leukemias, severe aplastic anemia, thalassemia, and inborn errors of metabolism. Since the first successful pediatric transplant in 1988, tens of thousands of cord blood transplants have been performed globally with established curative efficacy.

0:31:54supportedmoderateDr. Frans Kuypers on Placenta as a Source of Bankable Stem C

Placental-derived stem cells have been shown in laboratory studies to differentiate into cells exhibiting neuronal characteristics.

"So we have shown that um so they can become neurons. They become any cell that you want, in a sense, right? Because you're able to tease them. Now, whether they will be a functional brain cell, that's a different story, okay? Because if you if you show that cells get the characteristics of neurons in a petri dish, what you do in a stem cell lab, it does not necessarily mean that I can suddenly replace somebody's brain cell, okay?" (said at 0:31:54)

Multiple laboratory cell culture studies confirm that stem cells derived from human placental tissue (such as placental mesenchymal stem cells and human amniotic epithelial stem cells) can be induced in vitro to differentiate into cells exhibiting neuronal characteristics. In these experimental settings, induced cells display neuron-like morphology, express neuronal marker proteins (such as β-III tubulin, Nestin, and GFAP), and exhibit functional properties such as altered membrane potentials or neurotransmitter secretion. As the speaker appropriately cautions, demonstrating neuronal marker expression and morphology in vitro does not automatically translate to successful cell replacement or functional brain integration in vivo.

0:57:07supportedmoderateDr. Frans Kuypers on Placenta as a Source of Bankable Stem C

Funding for research from the National Institutes of Health (NIH) in the United States has declined or retracted over recent decades.

"Over the last decades, it's going down all the time, particularly creative research. And and the problem with that one is that new ideas—and it's not my idea, it's everybody's good idea—do not get developed in a way they should actually, as a society like we are, because we have much more potential than we actually banking on currently. And so the National Institutes of Health, as an example, has been retracting over time continuously." (said at 0:57:07)

Analyses of biomedical research funding trends in the United States show that following a rapid budget doubling period between 1994 and 2003, real (inflation-adjusted) funding growth slowed dramatically and purchasing power contracted. Reports tracking US biomedical research spending found that after 2003, growth rates sharply decelerated from 7.8% annually (1994–2003) to 3.4% (2003–2007), and when adjusted for inflation, combined public and private funding levels, including National Institutes of Health funding, experienced absolute contractions (such as an estimated 2% inflation-adjusted decrease in 2008).

1:05:17supportedmoderateDr. Frans Kuypers on Placenta as a Source of Bankable Stem C

Providing proper nutrition and supportive care to patients infected with Ebola significantly increases their chances of survival.

"what they found out that if you are able to give proper nutrition, proper care to a patient infected with Ebola, the chances of surviving really shoot up." (said at 1:05:17)

Published clinical evidence and outbreak management data demonstrate that early, optimized supportive care—consisting of fluid and electrolyte resuscitation, nutritional support, and management of secondary complications—significantly improves survival outcomes in patients with Ebola virus disease.

Fact-checked episodes

Publications